ATE511834T1 - Stealth lipid-nanokapseln, verfahren zu ihrer herstellung und ihre verwendung als träger von wirkstoff(en) - Google Patents

Stealth lipid-nanokapseln, verfahren zu ihrer herstellung und ihre verwendung als träger von wirkstoff(en)

Info

Publication number
ATE511834T1
ATE511834T1 AT03757174T AT03757174T ATE511834T1 AT E511834 T1 ATE511834 T1 AT E511834T1 AT 03757174 T AT03757174 T AT 03757174T AT 03757174 T AT03757174 T AT 03757174T AT E511834 T1 ATE511834 T1 AT E511834T1
Authority
AT
Austria
Prior art keywords
nanocapsules
lipid
carriers
lipid nanocapsules
production
Prior art date
Application number
AT03757174T
Other languages
English (en)
Inventor
Didier Hoarau
Pascal Delmas
Jean-Christophe Leroux
Original Assignee
Ethypharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Sa filed Critical Ethypharm Sa
Priority claimed from PCT/IB2003/003213 external-priority patent/WO2003103822A2/en
Application granted granted Critical
Publication of ATE511834T1 publication Critical patent/ATE511834T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AT03757174T 2002-06-11 2003-06-11 Stealth lipid-nanokapseln, verfahren zu ihrer herstellung und ihre verwendung als träger von wirkstoff(en) ATE511834T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0207175A FR2840532B1 (fr) 2002-06-11 2002-06-11 Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s)
US42111202P 2002-09-09 2002-09-09
PCT/IB2003/003213 WO2003103822A2 (en) 2002-06-01 2003-06-11 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)

Publications (1)

Publication Number Publication Date
ATE511834T1 true ATE511834T1 (de) 2011-06-15

Family

ID=29559140

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03757174T ATE511834T1 (de) 2002-06-11 2003-06-11 Stealth lipid-nanokapseln, verfahren zu ihrer herstellung und ihre verwendung als träger von wirkstoff(en)

Country Status (5)

Country Link
US (1) US20040076683A1 (de)
AT (1) ATE511834T1 (de)
DK (1) DK1531800T3 (de)
ES (1) ES2366978T3 (de)
FR (1) FR2840532B1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
FR2916974B1 (fr) 2007-06-11 2010-11-26 Univ Angers Procede de preparation de nanoparticules lipidiques
FR2916973B1 (fr) 2007-06-11 2010-02-26 Univ Angers Nanocapsules a coeur lipidique chargees en actif(s) hydrosoluble(s) ou hydrodispersible(s)
FR2939699B1 (fr) 2008-12-12 2011-05-06 Univ Angers Procede de preparation de nanoparticules lipidiques
CA2787054A1 (en) * 2010-01-11 2011-07-14 Center For Molecular Medicine And Immunology Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
CA2833413C (en) 2011-04-20 2020-09-22 The University Of Sydney A method for the treatment of a solid tumour
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
EP2788020A4 (de) 2011-12-05 2015-04-29 Immunomedics Inc Therapeutische verwendung von anti-cd22-antikörpern zur induktion von trogozytose
BR112015013444B1 (pt) 2012-12-13 2022-11-01 Immunomedics, Inc Uso de um imunoconjugado
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
FR3017294B1 (fr) * 2014-02-07 2021-10-01 Atlangram Nanoparticules lipidiques comprenant un antibiotique et leurs utilisations en therapie
JP6746845B2 (ja) 2015-04-22 2020-08-26 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 循環ｔｒｏｐ−２陽性癌細胞の単離、検出、診断及び／または特徴付け
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
US20170224837A1 (en) 2016-02-10 2017-08-10 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
AU2017257254B2 (en) 2016-04-27 2022-02-24 Immunomedics, Inc. Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
US10918734B2 (en) 2017-03-27 2021-02-16 Immunomedics, Inc. Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
FR3099069A1 (fr) * 2019-07-24 2021-01-29 Université D`Angers Procede continu de nano-emulsification par inversion de phase en concentration

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839175A (en) * 1986-07-28 1989-06-13 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
FR2608942B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5160669A (en) * 1988-03-03 1992-11-03 Micro Vesicular Systems, Inc. Method of making oil filled paucilamellar lipid vesicles
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6416740B1 (en) * 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6217886B1 (en) * 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
US20070077292A1 (en) * 2005-10-03 2007-04-05 Pinsky Mark A Compositions and methods for improved skin care

Also Published As

Publication number Publication date
DK1531800T3 (da) 2011-07-11
ES2366978T3 (es) 2011-10-27
FR2840532A1 (fr) 2003-12-12
FR2840532B1 (fr) 2005-05-06
US20040076683A1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
ATE511834T1 (de) Stealth lipid-nanokapseln, verfahren zu ihrer herstellung und ihre verwendung als träger von wirkstoff(en)
WO2003103822A3 (en) INDETECTABLE LIPID NANOCAPSULES, PROCESSES FOR THE PREPARATION THEREOF AND USE OF SUCH NANOCAPSULES AS A SUPPORT FOR ACTIVE INGREDIENT (S)
CA2468916A1 (en) A stable oxaliplatin solution formulation
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
CA2491216A1 (en) Method of producing a cationic liposomal preparation comprising a lipophilic compound
NO20015226L (no) Tri-aryl syrederivater som PPAR reseptor ligander, farmasoytisk sammensetning omfattende samme og anvendelse av samme for fremstilling av medikament.
EP0759694A4 (de) Verfahren zur in-vivo abgabe therapeutischer agenzien mittels liposomen
PL371282A1 (en) A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
DE60014162D1 (de) Fenofibrathaltige galenische arzneizusammensetzungen und verfahren zu ihrer herstellung
KR20010022708A (ko) 약물 수송에 이용할 수 있는 생분해가능한 주사용 블록공중합체 겔
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
KR101399341B1 (ko) 피부흡수 촉진용 양친매성 트리블록 공중합체, 이의 제조방법 및 이를 함유하는 화장료 조성물
IS6658A (is) Ný efnasambönd
CN101909655A (zh) 递送抗癌剂至细胞的方法
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
CN101792516A (zh) 生物可降解聚合物囊泡及其制备和应用
EP2767291A3 (de) Behandlung der Glykogenspeicherkrankheit Typ II
EP1539109B1 (de) Blockcopolymer-mizellenzusammensetzung mit verbesserter arzneimittelbeladungskapazität und verzögerter freisetzung
ATE326264T1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
EP0992509A3 (de) Neue Makrolidderivate
Zhang et al. Polymersomes: From Macromolecular Self‐Assembly to Particle Assembly
WO2003041682A3 (en) Lipid carrier compositions and methods for improved drug retention
AU2005204689A2 (en) Lipid compositions and use thereof
FR2776291B1 (fr) Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1531800

Country of ref document: EP